Benitec Biopharma Reports Positive Interim Results For BB-301 Gene Therapy In OPMD Clinical Trial
(RTTNews) - Benitec Biopharma Inc. (BNTC), a clinical-stage biotechnology company, Wednesday announced sustained improvements in swallowing function and reduced dysphagic symptoms following the administration of a low dose of BB-301 in three participants of its Phase 1b/2a clinic
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
